There are insufficient data on the use of oseltamivir phosphate in the treatment of pregnant women to permit evaluation of the potential for fetal malformations or fetal toxicities associated with oseltamivir phosphate. Therefore, oseltamivir phosphate should be administered to pregnant women only if the anticipated benefits outweigh the potential risks. Oseltamivir phosphate granules are primarily used for the treatment of influenza A and B in adults and children 1 year of age and older, and for the prevention of influenza A and B in adults and adolescents 13 years of age and older. Currently, there is insufficient clinical data on the treatment of pregnant women with oseltamivir phosphate granules. According to the available clinical data, this product has not shown any direct or indirect adverse effects on pregnancy, embryonic or postnatal development. However, pregnant women are a special population and should be evaluated for the safety of the drug, the expected benefit, the pathogenicity of the prevalent strains, and the underlying conditions of the pregnant woman to determine whether the product can be taken by a pregnant woman. If the expected benefits of taking the drug outweigh the potential dangers of the drug, it is recommended that the drug be applied under the guidance of a medical professional and in accordance with medical advice. The condition of the pregnant woman and the fetus should be monitored during the administration of the drug, and if there is any abnormality, the drug should be stopped immediately, and symptomatic treatment should be given in a timely manner.